N-803 (IL-15 Superagonist) — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-10 (month) in 3mo
ESTIMATED |
READOUT
A Study to Assess Anktiva in Patients With Long Covid-19.
Phase 2 · Long COVID |
IBRX ImmunityBio, Inc. | N-803 (IL-15 Superagonist) |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|